{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-019617","form_type":"8-K","ticker":"TARA","cik":"0001359931","company_name":"Protara Therapeutics, Inc.","filed_at":"2026-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.912834+00:00","generated_at":"2026-05-16T00:45:29.268537+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"TARA-002 shows 68% CR at 6 months in BCG-unresponsive NMIBC; no Grade 3+ TRAEs","bullets":["BCG-Unresponsive cohort: CR rate 68.2% at 6 months (15/22), 33.3% at 12 months (5/15); 61.5% re-induction conversion.","BCG-Naïve cohort: CR rate 66.7% at 6 months (18/27), 57.9% at 12 months (11/19); 66.7% re-induction conversion.","No Grade 3 or greater treatment-related adverse events; no discontinuations due to TRAEs; common TRAEs were dysuria (14%), bladder spasm (9%).","Enrollment completion of BCG-Unresponsive registrational cohort expected 2H 2026; ADVANCED-3 registrational trial for BCG-Naïve to start 2H 2026.","Data presented at ASCO GU 2026; company hosted conference call on Feb 24, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-019617","json":"https://secwatch.observer/filing/0001213900-26-019617.json","markdown":"https://secwatch.observer/filing/0001213900-26-019617.md","text":"https://secwatch.observer/filing/0001213900-26-019617.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1359931/000121390026019617/0001213900-26-019617-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1359931/000121390026019617/ea0277972-8k_protara.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:45:29.268537+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}